These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34854196)

  • 1. The treatment of refractory atypical bullous pemphigoid with generalized eczema and intense pruritus with dupilumab.
    Li W; Cai S; Man X
    Dermatol Ther; 2022 Feb; 35(2):e15243. PubMed ID: 34854196
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients.
    Miller AC; Temiz LA; Adjei S; Duran MA; Sassmannshausen J; Dominguez A; Thomas C; Schmidt JD; Bernhardt M; Doolittle-Amieva CJ; Moshiri AS; Thompson AJ; Pyoung Kim-Lim P; Mattia AV; Tyring SK
    J Drugs Dermatol; 2024 Jun; 23(6):e144-e148. PubMed ID: 38834228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter.
    Zhang Y; Zhang J; Chen J; Lin M; Gong T; Cheng B; Ji C
    Australas J Dermatol; 2021 Nov; 62(4):525-527. PubMed ID: 34448201
    [No Abstract]   [Full Text] [Related]  

  • 4. Case of atypical bullous pemphigoid with generalized pruritus and eczema as the prodrome for 10 years.
    Ikeda T; Okamoto K; Furukawa F
    J Dermatol; 2012 Aug; 39(8):720-1. PubMed ID: 22011062
    [No Abstract]   [Full Text] [Related]  

  • 5. Dupilumab for bullous pemphigoid with intractable pruritus.
    Seidman JS; Eichenfield DZ; Orme CM
    Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid.
    Wang Q; Ruan Y; Guo F; Zhu H; Pan M
    Acta Derm Venereol; 2023 Sep; 103():adv12324. PubMed ID: 37707294
    [No Abstract]   [Full Text] [Related]  

  • 7. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
    Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
    Front Immunol; 2020; 11():611549. PubMed ID: 33584689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study.
    Hu L; Huang R; Jiang F; You S; Wu Q
    Immun Inflamm Dis; 2023 Jul; 11(7):e924. PubMed ID: 37506153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.
    Yang J; Gao H; Zhang Z; Tang C; Chen Z; Wang L; Yang F; Chen S; He S; Liu S; Tang L; Xu Y; Hu Y; Ma L; Zhao Y; Luo X
    Dermatol Ther; 2022 Aug; 35(8):e15648. PubMed ID: 35715972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Dupilumab for the treatment of bullous pemphigoid.
    Wang M; Wang J; Shi B
    Dermatol Ther; 2022 Jul; 35(7):e15541. PubMed ID: 35478478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A severe case of IgA bullous pemphigoid successfully treated with dupilumab.
    Valenti M; De Giacomo P; Lavecchia A; Valenti G
    Dermatol Ther; 2022 Nov; 35(11):e15890. PubMed ID: 36181411
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
    Zhang Y; Xu Q; Chen L; Chen J; Zhang J; Zou Y; Gong T; Ji C
    Front Immunol; 2021; 12():738907. PubMed ID: 34721404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of eczema-like bullous pemphigoid and typical bullous pemphigoid with dupilumab: two case reports.
    Xu Y; Song W; Cai Y; Huang R; Wei J; Liu H; Peng X; Zeng K; Li C
    Int J Dermatol; 2023 Mar; 62(3):e144-e146. PubMed ID: 36214412
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab.
    Halling AS; Zachariae C; Thyssen JP
    Contact Dermatitis; 2020 Jul; 83(1):37-38. PubMed ID: 32087035
    [No Abstract]   [Full Text] [Related]  

  • 15. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report.
    Pop SR; Strock D; Smith RJ
    Dermatol Ther; 2022 Aug; 35(8):e15623. PubMed ID: 35669992
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe pemphigoid nodularis successfully treated with dupilumab.
    Jendoubi F; Bost C; Tournier E; Paul C; Konstantinou MP
    Dermatol Ther; 2022 Sep; 35(9):e15727. PubMed ID: 35861645
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature.
    Saleh M; Reedy M; Torok H; Weaver J
    Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A successful case of vesicular pemphigoid concurrent with pulmonary tuberculosis with dupilumab.
    Shan Y; Zuo YG
    Dermatol Ther; 2022 Apr; 35(4):e15330. PubMed ID: 35080079
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of immune checkpoint inhibitor-induced bullous pemphigoid.
    Apalla Z; Lallas A; Delli F; Lazaridou E; Papalampou S; Apostolidou S; Gerochristou M; Rigopoulos D; Stratigos A; Nikolaou V
    J Am Acad Dermatol; 2021 Feb; 84(2):540-543. PubMed ID: 32428613
    [No Abstract]   [Full Text] [Related]  

  • 20. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
    Klepper EM; Robinson HN
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.